Foreigners invest in the top 3 bio firms
CelltrionㆍSamsung BiologicsㆍSK Bioscience… Net purchases by foreigners in August ranked 4thㆍ8thㆍ10th Institutions CelltrionㆍSamsung Biologics, Individuals SK Bioscience
Foreign investors who distanced from Korean pharmaceutical and bio stocks this year are returning in August.
According to the Korea Exchange, foreign investors’ purchases of 29 stocks, more than half of the 45 pharmaceutical industry indexes in the securities market, exceeded sales in August.
The combined net purchases of foreign investors in 45 stocks amounted to KRW 544.2 billion, exceeding KRW 500 billion.
Foreign investors intensively bought the three major bio-leaders, Celltrion, Samsung Biologics, and SK Bioscience.
During this period, foreign investors’ net purchases of Celltrion were KRW 245.5 billion, the fourth largest among over 900 listed stocks.
Samsung Biologics’ net purchases by foreigners also exceed KRW 100 billion to KRW 133.7 billion. It is the eighth largest in the securities market.
At the same time, foreign investors’ net purchases of SK Bioscience also ranked 10th out of 900 stocks with KRW 99.3 billion.
GC Pharma’s net purchases by foreigners totaled KRW 30.6 billion, Daewoong Pharmaceutical KRW 29 billion, and Bukwang Pharmaceutical KRW 14.5 billion, over KRW 10 billion.
On the other hand, HanAll Biopharma recorded net selling of KRW 17.1 billion, Reyon Pharmaceutical KRW 16.8 billion, and Shinpoong Pharmaceutical KRW 11.8 billion.
Institutional investors also focused on large bio companies. They net purchased Celltrion and Samsung Biologics for KRW 281 billion and KRW 102.6 billion.
The net purchase of institutional investors of GC Pharma is KRW 55.9 billion, and Daewoong Pharmaceutical is KRW 13.6 billion.
However, institutions recorded a net selling of KRW 182.3 billion in SK Bioscience among the three major bio-caps, KRW 21.4 billion in Hanmi Pharmaceutical, and KRW 13.6 billion in Boryung Pharmaceutical.
Individuals invested the most in SK Bioscience, with KRW 80.8 billion in August. In addition, HanAll Biopharma was net bought KRW 17.4 billion, Reyon Pharmaceutical KRW 16.7 billion, Hanmi Pharmaceutical KRW 15.2 billion, and GeneOneLifeScience KRW 10.1 billion.
Celltrion had a net selling of KRW 519.6 billion by individual investors. It is the second-largest among 900 listed stocks in the securities market after Samsung SDI.
Furthermore, individual investors sold a net KRW 214.2 billion for Samsung Biologics, GC Pharma KRW 87 billion, Daewoong Pharmaceutical KRW 41.4 billion, Bukwang Pharmaceutical KRW 17 billion, and Pharmicell KRW 10.8 billion.